Answers are grounded in this paper and cite their sources.
This case highlights apixaban-related acute interstitial nephritis as a potential differential diagnosis for patients presenting with renal injury while on NOAC therapy.
Non-vitamin K oral anticoagulants (NOACs) are being increasingly prescribed. These drugs act rapidly, have predictable dose-related anticoagulation effect and require no routine laboratory monitoring, making them attractive for both patients and healthcare providers. All NOACs are at least partially excreted thought the kidneys. Renal injury related to NOAC use is being increasingly reported. NOAC-related acute interstitial nephritis (AIN) has only been reported once and that was in context of dabigatran use. We describe the first case of apixaban-related AIN. This case adds an important differential diagnoses that should be considered for any patient presenting with renal injury while being treated with NOACs.
No takes yet. Share an insight, caveat, or question.
Abdulhadi et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: